Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: A managed care cost-offset model

International Journal of Nephrology and Renovascular Disease

Volumn 6, Issue , 2013, Pages 79-87

  Mutell, Richard ^a   Rubin, Jaime L ^a   Bond, T Christopher ^a   Mayne, Tracy ^a  

^a DAVITA CLINICAL RESEARCH   (United States)

Author keywords

Dialysis; End stage renal disease; Hemodialysis; Hyperphosphatemia; Phosphate binders

Indexed keywords

FERRIC CITRATE; IRON; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST OFFSET MODEL; DIALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MANAGED CARE; MONTE CARLO METHOD;

EID: 84877074358     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S40729     Document Type: Article

References (22)

1. United States Renal Data System. The United States Renal Data System 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Minneapolis, MN: United States Renal Data System; 2011. Available from http://www.usrds.org/atlas11.aspx. Accessed May 15, 2011.
2. Rettig RA. Special treatment - the story of Medicare's ESRD entitlement. N Engl J Med. 2011;364(7):596-598.
3. Centers for Medicare and Medicaid Services (CMS), HHS. Medicare program; end-stage renal disease prospective payment system and quality incentive program; ambulance fee schedule; durable medical equipment; and competitive acquisition of certain durable medical equipment prosthetics, orthotics and supplies. Final rule. Fed Regist. 2011;76(218):70228-70316.
4. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519-530.
5. Dusso A, González EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011;25(4):647-655.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-S130.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201.
8. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-S145.
9. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002;17(2): 265-270.
10. Niecestro R, Chan K, Town W. A Phase II, randomized, double-blind, placebo-controlled dose ranging study of ferric citrate on serum phosphate levels in ESRD patients. J Am Soc Nephrol. 2006;17:76A.
11. Sinsakul M, Korbet S, Green T, Sika M, Lewis J. Iron absorption with higher doses of ferric citrate in controlling serum phosphorus in end-stage renal disease. Proceedings of the 2010 Spring Clinical Meetings of the National Kidney Foundation; April 13-17, 2010; Orlando, FL, USA.
12. Sinsakul M, Korbet S, Green T, Sika M, Lewis J. The safety and tolerability of higher doses of ferric citrate in controlling serum phosphate in end-stage renal disease patients. Proceedings of the 2010 Spring Clinical Meetings of the National Kidney Foundation; April 13-17, 2010; Orlando, FL, USA.
13. Niecestro R, Chiang SS, Chiang C, Chiang M, Town W. Long-term use of ferric citrate in end-stage renal disease patients. Proceedings of the 2010 Spring Clinical Meetings of the National Kidney Foundation; April 13-17, 2010; Orlando, FL, USA.
14. Sika M, Sinsakul MV, Niecestro RM, Chiang SS. Prolonged use of ferric citrate as a phosphate binder reduces intravenous iron use in patients with end-stage renal disease. J Am Soc Nephrol. 2010;21:783A.
15. Bond TC, Rubin J, Wang S, Niecestro RN, Poradosu E, Mayne TJ. Physician reaction to spontaneous rises in transferrin saturation and serum ferritin levels in end stage renal disease patients. J Am Soc Nephrol. 2011;22:728A.
16. The Red Book, Truven Health Analytics. New York, NY. http://www.redbook.com/redbook/ Accessed May 24, 2011.
17. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372-379.
18. Coyne DW, Kapoian T, Suki W, et al; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18(3):975-984.
19. Pizzi LT. Economic considerations in a changing anemia environment. Am J Kidney Dis. 2008;52(Suppl 6):S29-S33.
20. Epogen (epoetin alfa) [package insert]. Thousand Oaks, CA: Amgen, Inc; 2011.
21. St Peter WL, Fan Q, Weinhandl E, Liu J. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare and Medicaid services data. Clin J Am Soc Nephrol. 2009;4(12):1954-1961.
22. Kakuta T, Tanaka R, Hyodo T, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57(3):422-431.